Navigation Links
Arrayit Corporation Announces Manufacturing Breakthrough

SUNNYVALE, Calif., Dec. 22 /PRNewswire-FirstCall/ -- Arrayit Corporation (OTC Bulletin Board: ARYC), a life sciences and healthcare technology leader, today announced that the Company has made a technological breakthrough in the speed and efficiency by which it manufactures its proprietary microarrays, which are tiny glass substrates that contain rows and columns of printed spots used for scientific research and molecular diagnostics. The advance allows highly precise printing of as many as 2.4 million microarrays per year with a single robotic workstation, a significant increase over the Company's current capacity of 640,000 microarrays per instrument annually.

Arrayit Executive Vice President and Co-Founder Todd Martinsky stated, "This technological advance represents an engineering tour de force that combines our expertise in laboratory automation, linear drive robotics, micromachining, surface chemistry and contact printing. Leveraging our core tech competencies and patented contact printing platform in this manner should further enhance our competitive differentiation in the diagnostics market."

Arrayit is currently developing early stage definitive diagnostic tests for Ovarian Cancer, Parkinson's Disease, H1N1 and other illnesses. The Pre-Symptomatic Ovarian Cancer Diagnostic Test, OvaDx(TM), will be marketed and sold upon FDA approval by the Company's Houston-based subsidiary Arrayit Diagnostics, Inc. The worldwide market for OvaDx(TM) is estimated at 175 million microarray tests annually.

About Arrayit Corporation

Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 650 products to a customer base of more than 10,000 laboratories worldwide, including almost every major university, pharmaceutical and biotechnology company, major agricultural and chemical companies, government agencies, national research foundations and many private sector enterprises. Please visit for more information.

About Arrayit Diagnostics, Inc.

Houston-based Arrayit Diagnostics, Inc., a majority-owned subsidiary of Arrayit Corporation, is actively engaged in developing and commercializing a series of proprietary microarray-based diagnostic tests that provide for early detection of cancers, neurodegenerative diseases and other chronic and severe disease states.

Safe Harbor Statement

Except for historical information contained herein, statements made in this release that constitute forward-looking statements are based on currently available information, involve certain risks and uncertainties and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. Risks that may result from changes in the Company's business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K/A for the fiscal year ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended March 31, 2009, Form 10-Q/A for the fiscal second quarter ended June 30, 2009 and Form 10-Q for the fiscal third quarter ended September 30, 2009.

    Elite Financial Communications Group
    Dodi Handy, President and CEO (Twitter: @dodihandy)
    For Media Inquiries: Kathy Addison, Director, Elite Media Group (Twitter:
    407-585-1080 or via email at

SOURCE Arrayit Corporation

SOURCE Arrayit Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation
2. Arrayit to Mass Produce Rapid H1N1 Swine Flu Test Chip
3. Gibraltar Associates Named Agency of Record for Health Information and Diagnostic Provider PositiveID Corporation
4. Vivakor Announces Launch of VivaThermic Website and Highlights Distribution & Sales of Its VivaThermic Products in Japan Through Veritas Corporation
5. Neogen Corporation Announces 2nd Quarter Results
6. Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference
7. Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging
8. Raytheon BBN Technologies Licenses Stereo Digital Mammography Technology to FUJIFILM Corporation
9. RoundTable Healthcare Partners Announces Sale of Ascent Healthcare Solutions to Stryker Corporation
10. Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting
11. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
Post Your Comments:
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Cell Surface Marker ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/25/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... the United States (U.S.) Food ... candidate to Humira ® (adalimumab). Amgen believes this ... the FDA and represents Amgen,s first BLA submission using ... , M.D., executive vice president of Research and Development ...
(Date:11/25/2015)... , Nov. 25, 2015 AAIPharma Services ... investment of at least $15.8  Million to expand ... Wilmington, NC . The expansion will provide ... meet the growing demands of the pharmaceutical and ... site expansion will provide up to 40,000 square ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... ... 6:00 a.m. EST until 11:59 p.m. EST, customers will be racing the ... orders $80 or more to free gifts with purchases, there will be a new sale ... website for skin care and cosmetic needs, customers will save on already discounted prices. , ...
(Date:11/27/2015)... ... 27, 2015 , ... According to an article published November 13th ... in Washington D.C. revolved around the fact that proper dental care, both at-home and ... the link between periodontal disease (more commonly referred to as gum disease) and diabetes. ...
(Date:11/27/2015)... ... November 27, 2015 , ... The ... in America. As people age, more care is needed, especially with Alzheimer’s, dementia ... medical professionals are being overworked. The forgotten part of this equation: 80 percent ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... filthy the toilets were," said an inventor from Hillside, N.J. "Many people catch ... seat cover so that individuals will always be protected from germs." , He ...
(Date:11/27/2015)... ... , ... ProSidebar: Fashion is a set of 30 kinetic edge ... video editors can easily add an informative sidebar to any FCPX production. Create ... featuring self-animating drop zones, lines, bars, and text with the ease of FCPX's drag ...
Breaking Medicine News(10 mins):